idazoxan has been researched along with Parkinsonian Disorders in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (83.33) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hashimoto, M; Ono, H; Tanabe, M | 1 |
| Alam, M; Danysz, W; Dekundy, A; Schmidt, WJ | 1 |
| Buck, K; Ferger, B | 1 |
| Schmidt, WJ; Srinivasan, J | 3 |
6 other study(ies) available for idazoxan and Parkinsonian Disorders
| Article | Year |
|---|---|
Imidazoline I(1) receptor-mediated reduction of muscle rigidity in the reserpine-treated murine model of Parkinson's disease.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Benzazepines; Benzofurans; Clonidine; Disease Models, Animal; Dose-Response Relationship, Drug; Electromyography; Idazoxan; Imidazoles; Imidazoline Receptors; Injections, Intraperitoneal; Ligands; Male; Mice; Muscle Rigidity; Muscle, Skeletal; Parkinsonian Disorders; Reserpine; Time Factors; Yohimbine | 2008 |
Effects of glutamate and alpha2-noradrenergic receptor antagonists on the development of neurotoxicity produced by chronic rotenone in rats.
Topics: Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Basal Ganglia; Behavior, Animal; Catalepsy; Cyclopentanes; Disease Models, Animal; Dopamine; Excitatory Amino Acid Antagonists; Hypokinesia; Idazoxan; Male; Motor Activity; Muscle Rigidity; Neuroprotective Agents; Neurotoxicity Syndromes; Parkinsonian Disorders; Pyridines; Rats; Rats, Sprague-Dawley; Receptor, Metabotropic Glutamate 5; Receptors, Adrenergic, alpha-2; Receptors, Metabotropic Glutamate; Receptors, N-Methyl-D-Aspartate; Rotenone; Serotonin; Substantia Nigra; Time Factors | 2009 |
The selective alpha1 adrenoceptor antagonist HEAT reduces L-DOPA-induced dyskinesia in a rat model of Parkinson's disease.
Topics: Adrenergic alpha-1 Receptor Antagonists; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Antiparkinson Agents; Brain; Cerebrospinal Fluid; Disease Models, Animal; Dyskinesia, Drug-Induced; Idazoxan; Levodopa; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Plasma; Propranolol; Random Allocation; Rats; Rats, Wistar; Receptors, Adrenergic, alpha-1; Tetralones | 2010 |
The effect of the alpha2-adrenoreceptor antagonist idazoxan against 6-hydroxydopamine-induced Parkinsonism in rats: multiple facets of action?
Topics: Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Brain; Catalepsy; Disease Models, Animal; Dopamine; Exploratory Behavior; Hydroxyindoleacetic Acid; Idazoxan; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Prefrontal Cortex; Rats; Rats, Sprague-Dawley; Serotonin; Time Factors | 2004 |
Treatment with alpha2-adrenoceptor antagonist, 2-methoxy idazoxan, protects 6-hydroxydopamine-induced Parkinsonian symptoms in rats: neurochemical and behavioral evidence.
Topics: Adrenergic alpha-Antagonists; Analysis of Variance; Animals; Brain Chemistry; Catalepsy; Disease Models, Animal; Dopamine; Drug Interactions; Hydroxyindoleacetic Acid; Idazoxan; Male; Motor Activity; Norepinephrine; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Reaction Time; Serotonin; Statistics, Nonparametric | 2004 |
Serotonergic influence on the potentiation of D-amphetamine and apomorphine-induced rotational behavior by the alpha2-adrenoceptor antagonist 2-methoxy idazoxan in hemiparkinsonian rats.
Topics: Adrenergic Agents; Adrenergic alpha-2 Receptor Antagonists; Adrenergic alpha-Antagonists; Animals; Antiparkinson Agents; Apomorphine; Behavior, Animal; Dextroamphetamine; Drug Synergism; Idazoxan; Male; Motor Activity; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Serotonin; Sympatholytics | 2005 |